Tenaya Therapeutics develops gene therapies and cellular regeneration techniques to treat heart disease by targeting the underlying genetic causes of conditions such as hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. Their proprietary platforms aim to deliver curative treatments that improve heart function and enhance the quality of life for patients affected by these debilitating diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Heart diseases like hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC) often stem from underlying genetic defects, leading to impaired heart function and reduced quality of life. Current treatments primarily manage symptoms without addressing the root genetic causes of these conditions. This leaves a significant unmet need for therapies that can provide long-term curative benefits.
Solution
Tenaya Therapeutics is developing gene therapies to target the genetic drivers of heart disease, offering the potential for curative treatments. Their approach involves using adeno-associated virus (AAV) vectors to deliver functional genes to heart muscle cells, aiming to restore normal protein levels and improve heart function. By addressing the underlying genetic causes of conditions like MYBPC3-associated HCM and PKP2-associated ARVC, Tenaya's therapies seek to provide lasting benefits beyond symptom management. The company's clinical trials are evaluating the safety and efficacy of these gene therapies, with early data showing promising results in terms of gene delivery, RNA expression, and protein level increases.
Target Audience
The primary target audience includes patients diagnosed with genetically-driven heart diseases such as hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC), as well as the physicians and specialists who treat these conditions.
Features
- TN-201: AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM)
- TN-401: AAV9-based gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC)
- MyPEAK™-1: Phase 1b/2 clinical trial evaluating TN-201 for MYBPC3-associated HCM
- RIDGE™-1: Phase 1b clinical trial evaluating TN-401 for PKP2-associated ARVC
- AAV9 Capsid: Demonstrated robust delivery of transgenes to heart muscle cells
- Gene Therapy Platform: Aims to deliver fully functional genes to increase protein levels and address underlying disease